Merck Patent Gesellschaft MIT Beschrankter Haftung

Merck Patent Gmbh

Merck Patent Gesellschaft MIT Beschraenkter Haftung

Horst Juraszyk

Guido Melzer

Sabine Bernotat-Danielowski

Hanns Wurziger

Joachim Gante

Peter Raddatz

Dieter Dorsch

Werner Mederski

Christos Tsaklakidis

Hans-Peter Buchstaller

Rolf Gericke

Rolf Bergmann

Matthias Wiesner

Claus Fittschen

Johannes Gleitz

Rudolf Gottschlich

Helmut Wahlig

Elvira Dingeldein

Claus J Schmitges

Jurgen Seubert

Christopher Barnes

Inge Lues

Soheila Anzali

Wighard Strehlow

Johannes Gleiltz

Markus Woissyk

Peter Wendel

Christopher Bames

The invention relates to compounds of the formula Iin which R, R, R, Rand X have the meaning indicated in the text. The compounds act as inhibitors of factors Xa and VIIa and can therefore be employed for the control and prevention of thromboembolic conditions such as thrombosis, myocardial infarct, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and intermittent claudication.

Substituted biphenyl derivatives

The invention relates to semicarbazides of the general formula Iwhere R, R, R, Rand I have the meaning indicated in claim The compounds of the formula I can be employed as pharmaceutical active compounds in human and veterinary medicine, in particular for the control and prevention of thromboembolic disorders such as thrombosis, mycocardial infarct, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and intermittent claudication.

Aza-amino acid derivatives (factor Xa inhibitors 15)

Method for producing thienopyrimidines

Adhesion receptor antagonists

Benzamidine derivatives as factor XA inhibitors

Imidazo (4,5-C) pyridine-4-one derivatives with factor XA inhibiting effect

Biphenyl derivatives

Novel oxazolidinone derivatives of the formula I ##STR1## in which R.sup.1 is a phenyl radical which is unsubstituted or is monosubstituted by CN, H.sub.2 N--CH.sub.2 --, A.sub.2 N--CH.sub.2 --, H.sub.2 N--C(.dbd.NH)--, H.sub.2 N--C(.dbd.NH)--NH--, H.sub.2 N--C(.dbd.NH)--NH--CH.sub.2 --, HO--NH--C(.dbd.NH)-- or HO--NH--C(.dbd.NH)--NH--,

Adhesion receptor antagonists III

Novel piperazine derivatives of formula I:

Piperazine compounds as fibrinogen inhibitors

Compounds of the formula I ##STR1## wherein R.sup.1 and Y have the meanings indicated, and also their physiologically acceptable salts, inhibit the binding of fibrinogen to the corresponding receptor and can be employed for the treatment of thromboses, osteoporoses, oncoses, apoplexy, cardiac infarct, inflammations, arteriosclerosis and osteolytic disorders.

Compounds of the formula I ##STR1## wherein R.sup.1 and Y have the meanings indicated herein, and also their physiologically acceptable salts, inhibit the binding of fibrinogen to the corresponding receptor and can be employed for the treatment of thromboses, osteoporoses, oncoses, apoplexy, cardiac infarct, inflammations, arteriosclerosis and osteolytic disorders.

Compounds of the formula I ##STR1## in which R.sup.1 and X have the meanings herein defined, their physiologically unobjectionable salts and/or solvates inhibit the binding of fibrinogen to the corresponding receptor and can be employed for the treatment of thromboses, osteoporosis, tumoral diseases, apoplexy, cardiac infarction, inflammations, arteriosclerosis and osteolytic disorders.

Compounds of the formula I ##STR1## and the corresponding 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives, their physiologically acceptable salts and/or solvates, inhibit the binding of fibrinogen to the corresponding receptor and can be used for the treatment of thromboses, osteoporosis, oncoses, stroke, myocardial infarct, inflammations, arteriosclerosis and osteolytic disorders.

Growing community of inventors

Seeheim, Germany

Horst Juraszyk